Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.19 (GABA transaminase)
 808 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The influence of 2-(2-oxo-3-piperidyl)-1,2-benzisothiazoline-3-one-1, 1-dioxide (supidimide), a representative of a new class of sedative drugs, on the noradrenergic, dopaminergic, serotoninergic and gamma-aminobutyric acid (GABA)ergic neuronal systems of rodent brains was investigated. In each case the brain transmitter levels after administration of supidimide were determined. Utilisation of noradrenaline (norepinephrine, NE), dopamine (DA), and 5-hydroxytryptamine (5-HT) was also investigated ex vivo. The study was complemented with in vitro investigations of biosynthesis, synaptosomal uptake, degradation, and receptor binding of the transmitters. Based on a preliminary study of the distribution of [35S]-supidimide in rat brain, in vitro effects observed at greater than 10(-4) mol/l were considered irrelevant. Similarly, in vivo effects requiring dosages higher than 300 mg/kg i.p. were not regarded adequate to explain the sedative and antiaggressive efficacy of supidimide. With the above restrictions, the following parameters can be rated as not influenced by supidimide: levels of tryptophan in rat brain and serum (free and total); 5-HT biosynthesis in vivo (rat brain; 5-HT accumulation after monoamine oxidase (MAO) blockade); activity of MAO-A and MAO-B (rat brain mitochondria); uptake of 5-HT, NE and DA (rat synaptosomes); 5-HT receptor binding ( [3H]-LSD binding assay in rat cortical membranes); tyrosine hydroxylase activity (rat adrenal glands); catechol-O-methyl transferase (COMT) (rat liver); NE binding to central alpha 1- and alpha 2-receptors (rat brain; radioligand assay with [3H]-dihydroergocryptine, [3H]-prazosin and [3H]-WB 4101 (2',6'-dimethoxy-(G-3H]-phenoxy]-ethylaminomethylbenzo-1,4-dioxane ); DA levels (whole rat brain and striata); dihydroxyphenylacetic acid (DOPAC) levels (whole rat brain without cerebellum and striata); elevated DOPAC levels after pretreatment with haloperidol; DA-dependent adenylate cyclase in vitro (rat striatum); D2 receptor binding ( [3H]-spiperone binding assay, rat striatum); GABA levels (mouse brain); GABA transaminase activity (mouse brain stem); sodium-independent [3H]-GABA receptor binding (rat brain) and benzodiazepine binding (rat cortical membranes, [3H]-diazepam binding assay). Two effects on the GABAergic system were induced by supidimide. Starting at 300 mg/kg i.p., supidimide slowed down the GABA accumulation in brains of aminooxyacetate-treated mice. At 10(-4) mol/l supidimide caused a significant inhibition of GABA uptake (rat synaptosomes).(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Influence of supidimide on brain neurotransmitter systems of rats and mice. 608 11

(3-Hydroxybenzyl)hydrazine and methylhydrazine have been found to be potent slow-binding inhibitors of the pyridoxal 5-phosphate (PLP)-dependent enzyme gamma-aminobutyric acid aminotransferase (GABA-AT). Both compounds follow mechanism A (Morrison, J.F.; Walsh, C. T. Adv. Enzymol. 1988, 61, 201-301) which does not involve formation of a rapidly reversible enzyme-inhibitor complex before the formation of the final tight complex. The rate constant for formation of the enzyme-inhibitor complex determined from the slow-binding kinetics was 2.08 x 10(3) and 1.98 x 10(4) M-1 min-1 for methylhydrazine and (3-hydroxybenzyl)hydrazine, respectively. The rate constant for dissociation of the enzyme--inhibitor complex determined for the slow-binding kinetics was 4.6 x 10(-3) and 5 x 10(-3) min-1, respectively. The inhibition constants calculated from the slow-binding inhibition kinetics are 2.2 microM for methylhydrazine and 0.3 microM for (3-hydroxybenzyl)hydrazine. Reactivation of the inhibited enzyme was not first order, perhaps due to a side reaction of the hydrazine, but was consistent with the results obtained from the slow-binding kinetics. Inhibition constants were calculated from the level of enzyme activity at equilibrium inhibition. These constants are 2.8 and 0.46 microM for methylhydrazine and (3-hydroxybenzyl)hydrazine, respectively, in good agreement with those calculated from the slow-binding inhibition kinetics. 3-Hydrazinopropionate also behaved as a slow-binding inhibitor. However, the dependence of its kinetics on the concentration of inhibitor could not be described by the slow-binding or slow, tight-binding inhibition models. These kinetics could not be described by the tight-binding character of the inhibition because the addition of the competitive inhibitor propionic acid at 100 times its Ki did not affect the shape of the curve for inhibitor concentration dependence. The slow-binding inhibition appeared to require 2-4 molecules of 3-hydrazinopropionate/enzyme. The reactivation of enzyme inhibited by 3-hydrazinopropionate was first order with a rate constant of 6.9 x 10(-3) min-1. Its equilibrium inhibition constant was calculated to be < 20 nM. However, the inhibition constant calculated was dependent on the concentration of inhibitor because of the unusual character discussed above and may be much lower. Only 1 PLP/enzyme dimer reacted with methylhydrazine or (3-hydroxybenzyl)hydrazine, as indicated by Scatchard plots, or with 3-hydrazinopropionate, as shown by a spectrophotometric titration. Slow-binding inhibition does not appear to be the result of a significant enzyme conformational change because there is no change in the tryptophan fluorescence of GABA-AT upon binding either methylhydrazine or 3-hydrazinopropionate. Implications for the design of hydrazine inhibitors of GABA-AT are discussed.
 ...
PMID:Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues. 857 11